Santaris Bets on New Subsidiary to Bolster US Presence; Posts Higher Losses in '08 | GenomeWeb

Danish RNA drugs developer Santaris Pharma has begun setting up a San Diego, Calif.-based subsidiary in an effort to strengthen its position in the US, a company spokeswoman confirmed this week.

Although specific details about the unit were not available by press time, the spokeswoman said that it would be led by Chief Development Officer Arthur Levin, who was formerly senior vice president of drug development at antisense shop Isis Pharmaceuticals.

She added that Santaris expects to formally announce the subsidiary in the coming months.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.